In:
International Journal of Geriatric Psychiatry, Wiley, Vol. 31, No. 3 ( 2016-03), p. 316-322
Abstract:
Amyloid‐associated depression is associated with cognitive impairment cross sectionally. This follow‐up study was to determine the relationship between amyloid‐associated depression and the development of Alzheimer's disease (AD). Methods Two hundred and twenty three subjects who did not have dementia at baseline were given a repeat cognitive evaluation for incident AD. Depression was defined by having a Center for Epidemiological Studies Depression (CES‐D) score ≥ 16, and non‐amyloid vs. amyloid‐associated depression by having a low vs. high plasma amyloid‐β peptide 40 (Aβ40)/Aβ42 ratio. Apolipoprotein E (ApoE) genotype was determined, and antidepressant usage was documented. Results Fifteen subjects developed AD (7%) after an average follow‐up time of 6.2 years. While none of those with non‐amyloid depression developed AD, 9% of those with amyloid‐associated depression developed AD. Further, among those with amyloid‐associated depression, ApoE4 carriers tended to have a higher risk of AD than ApoE4 non‐carriers (40% vs. 4%, p = 0.06). In contrast, 8% of those who did not have depression at baseline developed AD, but ApoE4 carriers and non‐carriers did not show a difference in the AD risk. After adjusting for age, the interaction between ApoE4 and amyloid‐associated depression (β = +0.113, SE = 0.047, P = 0.02) and the interaction between ApoE4 and antidepressant use (β = +0.174, SE = 0.064, P = 0.007) were associated with the AD risk. Conclusions Amyloid‐associated depression may be prodromal depression of AD especially in the presence of ApoE4. Future studies with a larger cohort and a longer follow‐up are warranted to further confirm this conclusion. Copyright © 2015 John Wiley & Sons, Ltd.
Type of Medium:
Online Resource
ISSN:
0885-6230
,
1099-1166
Language:
English
Publisher:
Wiley
Publication Date:
2016
detail.hit.zdb_id:
1500455-7
